TVI-Brain-1 is under clinical development by TVAX Biomedical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect TVI-Brain-1’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 26 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TVI-Brain-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
TVI-Brain-1 is under development for the treatment of grade IV gliomas and glioblastoma. The therapeutic candidate is administered as intravenous infusion. It is developed based on TVAX immunotherapy platform that employs a unique combination of cancer cell vaccination and killer T-cell treatment.
It was in pediatrics for the treatment of high grade glioma
TVAX Biomedical overview
TVAX Biomedical is a company that develops drugs in the clinical stage cell-based on immunotherapy for treatment of cancer. It uses proprietary combination of cancer cell vaccination with killer T cell treatment. The company’s TVI-Brain-1 is a drug therapy used for the treatment of brain cancer. TVAX Biomedical is also developing therapy for treatment of kidney cancer. The company conducts clinical trials in key canine cancers to determine safety and usefulness of TVAX Immunotherapy as a treatment for wide range of canine cancer types. It also undertakes clinical trials for TVI-Kidney-1 to support its potential FDA approval. TVAX Biomedical is headquartered in Olathe, Kansas, the US.
Quick View TVI-Brain-1 LOA Data
|Highest Development Stage|